A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis

[1]  B. Davidson.  Prognostic factors in malignant pleural mesothelioma. , 2015, Human pathology.

[2]  Y. C. G. Lee.  Surgical resection of mesothelioma: an evidence-free practice , 2014, The Lancet.

[3]  N. Maskell,et al.  A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial , 2014, Trials.

[4]  B. Kiely,et al.  The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Creaney,et al.  Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma , 2013, British Journal of Cancer.

[6]  A. Musk,et al.  A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit , 2013, Pathology.

[7]  N. Maskell,et al.  Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients. , 2012, Chest.

[8]  M. J. van de Vijver,et al.  Prognosis and prognostic factors of patients with mesothelioma: a population-based study , 2012, British Journal of Cancer.

[9]  D. Prytherch,et al.  Routine Laboratory Tests can Predict In-hospital Mortality in Acute Exacerbations of COPD , 2011, Lung.

[10]  Hong Zhang,et al.  Malignant Pleural Mesothelioma: A Population-Based Study of Survival , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  N. Pavlakis,et al.  High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy , 2010, Clinical Cancer Research.

[12]  B. Kiely,et al.  Certain death in uncertain time: informing hope by quantifying a best case scenario. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Millward,et al.  A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters , 2010, Clinical Cancer Research.

[14]  A. Musk,et al.  Predicting survival in malignant mesothelioma , 2009, European Respiratory Journal.

[15]  M. Tattersall,et al.  Sustaining hope when communicating with terminally ill patients and their families: a systematic review , 2008, Psycho-oncology.

[16]  E. Shaw,et al.  Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Mori,et al.  Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy. , 2006, The Journal of urology.

[18]  J. Steele,et al.  Prognostic factors for mesothelioma. , 2005, Hematology/oncology clinics of North America.

[19]  K. Müller,et al.  Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register , 2004, International archives of occupational and environmental health.

[20]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M Nesti,et al.  Analysis of survival of mesothelioma cases in the Italian register (ReNaM). , 2003, European journal of cancer.

[22]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[23]  K R Abrams,et al.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems , 2000, Thorax.

[24]  K R Hess,et al.  Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Peggo K. W. Lam,et al.  Derivation of a prediction rule for post-traumatic acute lung injury. , 1999, Resuscitation.

[26]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[27]  J V Tu,et al.  Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. , 1996, Journal of clinical epidemiology.

[28]  J Hasford,et al.  CART and logistic regression analyses of risk factors for first dose hypotension by an ACE-inhibitor. , 1993, Therapie.

[29]  J. Shao.  Linear Model Selection by Cross-validation , 1993 .

[30]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[31]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[32]  Takuhiro Yamaguchi,et al.  Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. , 2011, Japanese journal of clinical oncology.

[33]  F. Ricceri,et al.  Survival of pleural malignant mesothelioma in Italy: A population‐based study , 2009, International journal of cancer.

[34]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.